Investigation of a clinical trial drug VV261 as a potent antiviral candidate against Chikungunya virus
Abstract
Chikungunya virus (CHIKV) is a single-strand positive-sense RNA virus belonging to the family Togaviridae. Since 2004, CHIKV outbreaks have become more frequent and widespread, affecting millions of people and establishing Chikungunya disease as a significant global public health issue. 1 In Asia, the Asian lineage (CHIKV-Asian) and the East-Central-South-African lineage (CHIKV-ECSA) have become the most prevalent. In July 2025, a large-scale outbreak occurred in Guangdong Province, China, resulting in more than 9000 confirmed cases. 2 To date, no drug has been approved for clinical therapy, highlighting the urgent need to develop effective treatments against CHIKV.
Fields of Study & Subjects
Mosquito-borne diseases and control
Diverse Scientific Research Studies
Biological Research and Disease Studies
Publication details
- Journal / source
- Signal Transduction and Targeted Therapy
- Publisher
- Springer Science and Business Media LLC
- Volume
- 11
- Issue
- 1
- Pages
- 56–56
- Publication date
- 11 February 2026
- Language
- EN